CPT code 81206 – BCR/ABL1 major breakpoint analysis

Key takeaways

CPT Code 81206 reports BCR/ABL1 translocation analysis at the major breakpoint (p210), whether the lab runs it qualitatively or quantitatively.

Codes 81206, 81207 and 81208 differ by breakpoint type (major, minor, other), so the test method never decides between them.

81206 is a Tier 1 molecular pathology code (81200-81383), and Medicare pays it under the Clinical Laboratory Fee Schedule.

Pabau, the practice management platform we build, submits claims electronically through Claim.MD and tracks their status.

CPT code 81206: official descriptor and Tier 1 classification

CPT Code 81206 is a Tier 1 molecular pathology code in the 81200-81383 range of the AMA CPT code set. The official descriptor reads: BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative.

The phrase that decides the code is “major breakpoint.” Nearly all CML cases carry a fusion at the major breakpoint cluster region (M-bcr), which produces the p210 protein. CPT 81206 covers that transcript whether the lab reports a detected result at diagnosis or a measured level during treatment.

The two neighboring codes cover the other breakpoints. CPT 81207 reports the minor breakpoint (m-bcr, p190), which most Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) cases carry. CPT 81208 reports any other breakpoint, such as the rare p230 transcript.

All three descriptors say “qualitative or quantitative,” so the method never changes the code. The breakpoint named in the lab report does. The chart below walks through both decisions, starting with whether the test was molecular at all.

Clinical indications: when is CPT 81206 used?

Physicians order CPT Code 81206 to detect or measure the major-breakpoint BCR/ABL1 transcript. Each indication below must be documented in the medical record to support medical necessity.

• New CML diagnosis: When the blood count or cytogenetics suggest CML, RT-PCR confirms the p210 transcript before tyrosine kinase inhibitor (TKI) therapy begins.
• Molecular monitoring on TKI therapy: Quantitative RT-PCR reports p210 transcript levels on the International Scale (IS). These serial tests are reported with 81206, not 81207.
• Ph+ ALL with a p210 transcript: Roughly 25-30% of adult ALL cases carry BCR/ABL1. Most produce p190 and bill 81207, but a minority carry p210 and bill 81206.
• Suspected relapse or loss of response: A rising transcript level or new clinical signs justify retesting the major breakpoint in a patient previously in remission.

National Comprehensive Cancer Network (NCCN) guidelines for CML treat molecular testing at diagnosis and quantitative monitoring during TKI therapy as standard care. That supports medical necessity when the order documents the presentation and the reason for testing.

ICD-10-CM diagnosis codes paired with CPT 81206

Every CPT 81206 claim needs an ICD-10-CM code that states the clinical reason for the test. Payers check medical necessity at the diagnosis-code level, so an unspecified or mismatched code is a leading denial trigger.

Verify each code in the CDC/NCHS ICD-10-CM web tool before submission. Pick the C92.1x or C91.0x code that matches the remission status on the date of service, rather than an unspecified leukemia code.

Medicare coverage and reimbursement for CPT Code 81206

Medicare covers BCR/ABL1 major-breakpoint analysis when the claim meets the medical necessity criteria of the Medicare Administrative Contractor (MAC). Local Coverage Determinations (LCDs) for molecular pathology set those rules, so they vary by MAC jurisdiction. Confirm which LCD applies to the performing lab before billing.

Medicare pays CPT 81206 under the CMS Clinical Laboratory Fee Schedule (CLFS), not the Physician Fee Schedule. Lab codes carry no work RVUs, so look up the payment limit in the CLFS file for the quarter of the date of service.

Pabau submits 81206 claims electronically through Claim.MD, the US clearinghouse it connects to, and tracks their status.

Prior authorization requirements

Medicare fee-for-service does not generally require prior authorization (PA) for CPT 81206, but many Medicare Advantage and commercial plans do. Confirm the rules before ordering with an insurance eligibility verification that captures the plan-level PA rules, not just general coverage.

• Clinical documentation for PA requests: the physician order with the clinical indication and relevant CBC and cytogenetics results. Add the treating oncologist’s note on the suspected or confirmed diagnosis.
• Turnaround: processing times vary by payer. Urgent cases may qualify for expedited review if the urgency is documented explicitly.
• Medicare Advantage plans: each plan sets its own PA rules. Assume PA is required unless the plan’s provider portal confirms otherwise for this code.

Documentation requirements for billing CPT 81206

Payers deny 81206 claims when the record does not show which breakpoint was tested or why. Knowing the full medical billing workflow for molecular pathology helps staff collect the right records before the claim goes out.

Required documentation for a defensible 81206 claim:

• Physician order: signed and dated, naming BCR/ABL1 major-breakpoint (p210) testing and the clinical reason, such as diagnosis or monitoring.
• Laboratory report: names the method (RT-PCR or another nucleic-acid amplification method), the specimen type, the breakpoint analyzed, and a qualitative or IS% result.
• Supporting clinical note: the treating physician’s note on the patient’s presentation, relevant blood findings, and the reason for molecular testing.
• ICD-10-CM code linkage: the diagnosis on the claim must match the indication documented in the clinical note.
• Prior authorization number: if PA was obtained, attach the reference number to the claim before submission.

FISH for t(9;22) is a cytogenetic test, reported with 88271 and 88275 rather than 81206. Keep those codes off a claim for a PCR-based BCR/ABL1 assay.

Keeping documentation aligned with medical billing compliance standards reduces audit exposure, particularly for molecular pathology claims that attract MAC post-payment review.

Common denial reasons for CPT Code 81206 claims

Denial patterns for CPT Code 81206 repeat across payers and MAC jurisdictions. Effective denial management in healthcare starts with finding which of these causes drives your rejections.

How to appeal a denied CPT 81206 claim

Most payers allow at least one level of administrative appeal, and Medicare runs a five-level process. The denial codes on the remittance advice tell you which appeal argument to make.

1. Pull the remittance advice: find the Claim Adjustment Reason Code (CARC). CO-4 means the procedure code is inconsistent with the modifier, or a required modifier is missing.
2. Read the other common CARCs: CO-50 means the payer judged the service not medically necessary. CO-97 means the payment is included in another service already adjudicated.
3. Gather supporting documentation: the physician order, the lab report naming the breakpoint and method, and the clinical note. Add any NCCN guideline page that supports testing at this stage.
4. Draft a letter of medical necessity: the treating oncologist signs a letter stating the indication, the test ordered, and how the result informed treatment decisions.
5. Reference the applicable LCD: cite the MAC’s Local Coverage Determination for molecular pathology by document number and effective date.
6. Submit within payer deadlines: Medicare allows 120 days from receipt of the initial determination to request a redetermination. Commercial deadlines vary, so check each plan’s policy.

Billing tips to maximize reimbursement for CPT Code 81206

Getting paid correctly for CPT Code 81206 depends on clean claim construction and a steady order-entry workflow. The tips below address the most common leakage points, and claims software for billers helps your team act on them.

• Verify coverage before the test is ordered: confirm the patient’s plan covers CPT 81206 for the documented diagnosis. Policies differ between plans, even within one insurer.
• Code from the breakpoint, not the method: read the lab report for p210, p190 or another transcript before choosing 81206, 81207 or 81208.
• Check ICD-10 specificity at order entry: entering the right C92.1x code at the time of the order prevents most diagnosis mismatch denials.
• Attach the PA number at claim creation: build it into the claim when PA confirmation arrives, rather than adding it by hand later.
• Bill one code per breakpoint type: a multiplex assay that analyzes both p210 and p190 can support 81206 and 81207. Check NCCI edits and payer policy first. Qualitative and quantitative runs on the major breakpoint still bill a single 81206.
• Submit through Claim.MD and watch status: Pabau submits claims electronically through Claim.MD and tracks their status, so rejections reach your team quickly.
• Use the AAPC code lookup for modifier guidance: the AAPC Codify CPT lookup lists applicable modifiers and payer notes for molecular pathology codes.
• Aim for first-pass acceptance: a claim accepted on first submission skips the rework cycle. Our guide to submitting a clean claim explains what that takes.

How claims management software reduces denials for CPT code 81206

Many lab and oncology billing teams build 81206 claims by hand from the order and the lab report. A wrong breakpoint code or a missing PA number then shows up weeks later as a denial.

Pabau keeps the patient record and the claim in one system. It submits claims through Claim.MD and tracks their status.

Your coders run the breakpoint, diagnosis and PA checks in this guide before each claim goes out. When a rejection comes back, they see it in Pabau and can correct it while the details are fresh.

Keep CPT 81206 claims moving

See how Pabau submits claims electronically through Claim.MD and tracks their status.

Book a demo

Conclusion

Code 81206 from the breakpoint the lab tested, and the most common error on this code family goes away. The major breakpoint (p210) is 81206 whether the result is qualitative or quantitative. The minor breakpoint (p190) is 81207, and any other transcript is 81208.

The trade-off is documentation. When a lab report omits the breakpoint, a coder cannot choose the right code and a payer cannot verify it. Ask your lab to name the transcript on every report, and build the PA and diagnosis checks into order entry.

Book a demo to see how Pabau submits claims through Claim.MD and tracks their status.

Continue your research

Need to understand how clearinghouse submission works end to end? Medical claims clearinghouse overview explains how electronic claim routing, validation, and ERA processing connect payers to your billing system.

Seeing recurring denials on your 835 remittance files? Electronic remittance advice (ERA) guide breaks down how to read CARC and RARC codes and route denial corrections efficiently.

Want the bigger picture behind each 81206 claim? Revenue cycle management fundamentals covers the end-to-end process from eligibility through collections.

Billing a molecular test with no Tier 1 code? CPT code 81479 billing guide covers the unlisted molecular pathology code and the documentation payers expect with it.

Frequently asked questions